JOINT Corp (JYNT) stock
JYNTNasdaqPatent Owners & LessorsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 10/309% below fair value
$7.03−0.33 (-4.48%)
Close on Oct 30, 2026Market cap $99.43MP/E 26.0Yield –
Earnings
Joint's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Nov 5, 2026
Q3 FY2026 · estimated, after the close
Revenue, Q2 FY2026
$15.20M
+14.3% on a year earlier
EPS, Q2 FY2026
$0.05
$0.01 a year earlier
Latest guidance
Lowered
Aug 6, 2026 · 4 items
Quarterly results
Revenue and earnings per share from each of Joint's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026Expected | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026after the close | $15.20M | +14.3% | $0.05 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026after the close | $14.80M | +13.0% | $0.09 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 12, 2026after the close | $15.20M | +5.6% | $0.07 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025after the close | $13.40M | -55.6% | $0.06 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025after the close | $13.30M | -56.1% | $0.01 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025after the close | $13.10M | -55.9% | $0.05 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 13, 2025after the close | $14.40M | -52.9% | $0.06 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024after the close | $30.20M | +2.4% | -$0.21 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024after the close | $30.30M | – | -$0.24 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 2, 2024after the close | $29.70M | +4.2% | $0.06 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 7, 2024after the close | $30.60M | +10.1% | -$0.75 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 9, 2023after the close | $29.50M | +10.9% | -$0.05 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 10, 2023after the close | – | – | – | Release |
| Q1 FY2023ended Mar 31, 2023 | May 4, 2023after the close | $28.50M | +27.2% | $0.15 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 9, 2023after the close | $27.80M | +24.1% | $0.04 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022after the close | $26.60M | +26.7% | $0.03 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022after the close | $25.10M | – | $0.02 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022after the close | $22.40M | – | -$0.01 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 24, 2022after the close | $22.40M | – | $0.01 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021after the close | $21.00M | – | $0.13 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 6, 2021after the close | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 4, 2021after the close | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020after the close | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 6, 2020after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Joint's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| System-wide sales | FY2026 | $519.00M – $552.00M | $519.00M – $552.00M | Reaffirmed | Aug 6, 2026 |
| System-wide comp sales for clinics open 13 months or more | FY2026 | -3% – +3% | -3% – +3% | Reaffirmed | Aug 6, 2026 |
| Consolidated Adjusted EBITDAnon-GAAP | FY2026 | $12.50M – $13.50M | $12.50M – $13.50M | Reaffirmed | Aug 6, 2026 |
| New franchised clinic openings, excluding the impact of refranchised clinics | FY2026 | 22 – 26 | 30 – 35 | Lowered | Aug 6, 2026 |
Guidance history
Every forecast Joint put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Aug 6, 2026 | System-wide comp sales for clinics open 13 months or more | FY2026 | -3% – +3% | Reaffirmed |
| Aug 6, 2026 | Consolidated Adjusted EBITDA | FY2026 | $12.50M – $13.50M | Reaffirmed |
| Aug 6, 2026 | New franchised clinic openings, excluding the impact of refranchised clinics | FY2026 | 22 – 26 | Lowered |
| Aug 6, 2026 | System-wide sales | FY2026 | $519.00M – $552.00M | Reaffirmed |
| May 7, 2026 | System-wide comp sales for clinics open 13 months or more | FY2026 | -3% – +3% | Reaffirmed |
| May 7, 2026 | Consolidated Adjusted EBITDA | FY2026 | $12.50M – $13.50M | Reaffirmed |
| May 7, 2026 | New franchised clinic openings, excluding the impact of refranchised clinics | FY2026 | 30 – 35 | Reaffirmed |
| May 7, 2026 | System-wide sales | FY2026 | $519.00M – $552.00M | Reaffirmed |
| Mar 12, 2026 | System-wide comp sales for clinics open 13 months or more | FY2026 | -3% – +3% | New |
| Mar 12, 2026 | Consolidated Adjusted EBITDA | FY2026 | $12.50M – $13.50M | New |
| Mar 12, 2026 | New franchised clinic openings, excluding the impact of refranchised clinics | FY2026 | 30 – 35 | New |
| Mar 12, 2026 | System-wide sales | FY2026 | $519.00M – $552.00M | New |
| Nov 6, 2025 | Comp sales | FY2025 | -1% – 0% | New |
| Nov 6, 2025 | Consolidated Adjusted EBITDA | FY2025 | $10.80M – $11.80M | New |
| Nov 6, 2025 | New clinic openings | FY2025 | 30 – 35 | New |
| Nov 6, 2025 | System-wide sales | FY2025 | $530.00M – $534.00M | New |
| Aug 7, 2025 | Consolidated Adjusted EBITDA | FY2025 | $10.80M – $11.80M | Raised |
| Aug 7, 2025 | New franchised clinic openings | FY2025 | 30 – 35 | Lowered |
| Aug 7, 2025 | System-wide sales | FY2025 | $530.00M – $550.00M | Lowered |
| May 8, 2025 | Consolidated Adjusted EBITDA | FY2025 | $10.00M – $11.50M | Reaffirmed |
| May 8, 2025 | New franchised clinic openings, excluding the impact of refranchised clinics | FY2025 | 30 – 40 | Reaffirmed |
| May 8, 2025 | System-wide sales | FY2025 | $550.00M – $570.00M | Reaffirmed |
| Mar 13, 2025 | Consolidated Adjusted EBITDA | FY2025 | $10.00M – $11.50M | New |
| Mar 13, 2025 | New franchised clinic openings | FY2025 | 30 – 40 | New |
| Mar 13, 2025 | System-wide sales | FY2025 | $550.00M – $570.00M | New |
| Nov 7, 2024 | System-wide comp sales for all clinics open 13 months or more | FY2024 | +3% – +4% | New |
| Nov 7, 2024 | New franchised clinic openings, excluding the impact of refranchised clinics | FY2024 | 55 – 60 | Lowered |
| Nov 7, 2024 | System-wide sales | FY2024 | $525.00M – $535.00M | Lowered |
| Aug 8, 2024 | New franchised clinic openings | FY2024 | 60 – 75 | Reaffirmed |
| Aug 8, 2024 | System-wide sales | FY2024 | $530.00M – $545.00M | Reaffirmed |
| May 2, 2024 | new franchised clinic openings | FY2024 | 60 – 75 | Reaffirmed |
| May 2, 2024 | System-wide sales | FY2024 | $530.00M – $545.00M | Reaffirmed |
| Mar 7, 2024 | new franchised clinic openings | FY2024 | 60 – 75 | New |
| Mar 7, 2024 | System-wide sales | FY2024 | $530.00M – $545.00M | New |
| Nov 9, 2023 | Adjusted EBITDA | FY2023 | $11.00M – $12.50M | Lowered |
| Nov 9, 2023 | Franchised clinic openings | FY2023 | 100 – 120 | Raised |
| Nov 9, 2023 | Company-owned or managed greenfield clinic openings | FY2023 | 8 – 12 | Lowered |
| Nov 9, 2023 | Revenue | FY2023 | $115.00M – $118.00M | Lowered |
| May 4, 2023 | Adjusted EBITDA | FY2023 | $12.50M – $14.00M | Reaffirmed |
| May 4, 2023 | Franchised clinic openings | FY2023 | 100 – 120 | Raised |
| May 4, 2023 | Company-owned or managed greenfield clinic openings | FY2023 | 8 – 12 | Lowered |
| May 4, 2023 | Revenue | FY2023 | $123.00M – $128.00M | Reaffirmed |
| Mar 9, 2023 | Adjusted EBITDA | FY2023 | $12.50M – $14.00M | New |
| Mar 9, 2023 | Franchised clinic openings | FY2023 | 100 – 120 | New |
| Mar 9, 2023 | Company-owned or managed greenfield clinic openings | FY2023 | 8 – 12 | Lowered |
| Mar 9, 2023 | Revenue | FY2023 | $123.00M – $128.00M | New |
| Nov 3, 2022 | Adjusted EBITDA | FY2022 | $11.50M – $12.50M | Lowered |
| Nov 3, 2022 | Franchised clinic openings | FY2022 | 110 – 130 | Raised |
| Nov 3, 2022 | Company-owned or managed clinic increases | FY2022 | 30 – 40 | Lowered |
| Nov 3, 2022 | Revenue | FY2022 | $100.00M – $102.00M | Raised |
| Aug 4, 2022 | Adjusted EBITDA | FY2022 | $12.00M – $14.00M | Reaffirmed |
| Aug 4, 2022 | Franchised clinic openings | FY2022 | 110 – 130 | Raised |
| Aug 4, 2022 | Company-owned or managed clinic increases | FY2022 | 30 – 40 | Lowered |
| Aug 4, 2022 | Revenue | FY2022 | $98.00M – $102.00M | Lowered |
| May 5, 2022 | Adjusted EBITDA | FY2022 | $12.00M – $14.00M | Lowered |
| May 5, 2022 | Franchised clinic openings | FY2022 | 110 – 130 | Raised |
| May 5, 2022 | Company-owned or managed clinic increases | FY2022 | 30 – 40 | Lowered |
| May 5, 2022 | Revenue | FY2022 | $98.00M – $102.00M | New |
| Feb 24, 2022 | Adjusted EBITDA | FY2022 | $15.00M – $17.00M | New |
| Feb 24, 2022 | Franchised clinic openings | FY2022 | 130 – 140 | New |
| Feb 24, 2022 | Company-owned or managed clinic increases | FY2022 | 30 – 40 | Lowered |
| Feb 24, 2022 | Revenue | FY2022 | $102.00M – $106.00M | New |
| Nov 4, 2021 | Adjusted EBITDA | FY2021 | $13.00M – $14.00M | New |
| Nov 4, 2021 | franchised clinic openings | FY2021 | 105 – 115 | New |
| Nov 4, 2021 | company-owned or managed clinic increases | FY2021 | 25 – 35 | Lowered |
| Nov 4, 2021 | Revenue | FY2021 | $80.00M – $81.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Joint filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- News
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- News
- Update